Beta-amyloid (Aβ42) and tau biomarkers can be detected in cerebrospinal fluid (CSF) to analyze early AD pathogenesis but are limited due to the invasiveness of lumbar punctures and its large margin of error for a definitive diagnosis [3,5,6,7]. The gene discussed is MAPT; the disease is Alzheimer disease.